Resumo As inovações em dispositivos ao longo das últimas décadas proporcionaram uma melhora no diagnóstico e tratamento de pacientes com insuficiência cardíaca. Essas novas ferramentas progressivamente adaptaram-se a estratégias minimamente invasivas e as opções percutâneas multiplicaram-se de forma rápida. No presente artigo revisamos as direções atuais e futuras dos dispositivos utilizados como opções adjuvantes para o diagnóstico e tratamento adjuvante na insuficiência cardíaca crônica, o seu desenvolvimento, mecanismos e estudos mais recentes adaptaramse adaptaram se multiplicaramse multiplicaram rápida crônica desenvolvimento

Abstract Innovations in devices during the last decade contributed to enhanced diagnosis and treatment of patients with cardiac insufficiency. These tools progressively adapted to minimally invasive strategies with rapid, widespread use. The present article focuses on actual and future directions of device-related diagnosis and treatment of chronic heart failure. insufficiency rapid use devicerelated device related failure

Abstract Introduction: The Technical Performance Score (TPS) was developed and subsequently refined at the Boston Children's Hospital. Our objective was to translate and validate its application in a developing country. Methods: The score was translated into the Portuguese language and approved by the TPS authors. Subsequently, we studied 1,030 surgeries from June 2018 to October 2020. TPS could not be assigned in 58 surgeries, and these were excluded. Surgical risk score was evaluated using Risk Adjustment in Congenital Heart Surgery (or RACHS-1). The impact of TPS on outcomes was studied using multivariable linear and logistic regression adjusting for important perioperative covariates. Results: Median age and weight were 2.2 (interquartile range [IQR] = 0.5-13) years and 10.8 (IQR = 5.6-40) kilograms, respectively. In-hospital mortality was 6.58% (n=64), and postoperative complications occurred in 19.7% (n=192) of the cases. TPS was categorized as 1 in 359 cases (37%), 2 in 464 (47.7%), and 3 in 149 (15.3%). Multivariable analysis identified TPS class 3 as a predictor of longer hospital stay (coefficient: 6.6; standard error: 2.2; P=0.003), higher number of complications (odds ratio [OR]: 1.84; 95% confidence interval [CI]: 1.1-3; P=0.01), and higher mortality (OR: 3.2; 95% CI: 1.4-7; P=0.004). Conclusion: TPS translated into the Portuguese language was validated and showed to be able to predict higher mortality, complication rate, and prolonged postoperative hospital stay in a high-volume Latin-American congenital heart surgery program. TPS is generalizable and can be used as an outcome assessment tool in resource diverse settings.

O uso de stents intravasculares em crianças com cardiopatia congênita é procedimento bem estabelecido, porém a indicação de paliação por meio de procedimentos percutâneos ao invés da cirurgia convencional permanece incerta. Neste relato são apresentados três casos de obstrução crítica de via de saída do ventrículo direito (VSVD), submetidos a ampliação da VSVD com implante de stent. O implante foi realizado com sucesso nos três casos, permitindo restabelecer o fluxo pulmonar para a árvore pulmonar e melhorar a saturação de oxigênio.

The use of intravascular stents in children with congenital heart disease is well established, however the use of palliative percutaneous therapy instead of a conventional surgery remains uncertain. We present three cases of critical right ventricular outflow tract (RVOT) obstruction treated with stenting to expand the RVOT. Stenting was successful in all three cases, reestablishing pulmonary flow into the pulmonary arteries and improving oxygen saturation.

INTRODUÇÃO: O acesso através da punção da artéria axilar (AAx) tem sido utilizado em adultos com bons resultados, porém seu uso em neonatos e lactentes jovens tem sido pouco relatado. Nosso objetivo foi relatar a experiência inicial com o uso desse acesso em diferentes intervenções nessa faixa etária de pacientes. MÉTODO: De janeiro de 2009 a setembro de 2010 foram incluídas 11 crianças submetidas a diferentes procedimentos intervencionistas realizados através de punção da AAx. O procedimento foi realizado com agulha 21 G, sendo utilizados introdutores 4 F ou 5 F pediátricos. RESULTADOS: A média de idade foi de 26 ± 12 dias e o peso médio, de 4,2 ± 1,7 kg. Os procedimentos intervencionistas realizados foram: implante de stent no canal arterial (6), valvoplastia aórtica (1), angioplastia aórtica (2), implante de stent em Blalock-Taussig (1), e redilatação do stent do canal arterial (1). A punção da AAx direita foi realizada com sucesso em todos os pacientes e sem dificuldade técnica. Os tempos médios do procedimento e da fluoroscopia foram de, respectivamente, 52 ± 15 minutos e 13 ± 4 minutos. Apenas um paciente teve como complicação um pneumotórax sem repercussão hemodinâmica, e os demais pacientes não apresentaram intercorrências. Não houve complicações isquêmicas nem neurológicas no membro puncionado. O tempo médio de internação na Unidade de Tratamento Intensivo (UTI) foi de 48 ± 16 horas. Não houve mortalidade durante os procedimentos intervencionistas e um paciente faleceu na UTI cinco dias após por sepse. CONCLUSÃO: O acesso axilar obtido por punção demonstrou ser uma alternativa segura e eficaz para a realização de diferentes procedimentos intervencionistas em neonatos e lactentes com cardiopatias congênitas.

BACKGROUND: Axillary artery access (AxA) has been used in adults with good results, however, its use in neonates and infants has not been extensively reported. This study was aimed at reporting our initial experience using this access in different cardiac interventions in this age group. METHOD: From January 2009 to September 2010, 11 children were submitted to different cardiac interventions using AxA. The procedure was performed with a 21 G needle followed by the insertion of a 4 F or a 5 F pediatric sheats. RESULTS: Mean age was 26 ± 12 days and mean weight was 4.2 ± 1.7 Kg. The cardiac interventions performed were: stenting of the arterial duct (6), aortic valvoplasty (1), aortic angioplasty (2), stent implantation in a Blalock-Taussig shunt (1) and stent redilation in the arterial duct (1). Right AxA puncture was successfully obtained in all patients without technical difficulties. Mean procedure and fluoroscopy times were 52 ± 15 minutes and 13 ± 4 minutes, respectively. Pneumothorax without hemodynamic involvement was the single complication in one patient. The other patients did not have any abnormalities. There were no ischemic or neurologic complications in the ipsilateral limb. Mean time of Intensive Care Unit (ICU) stay was 48 ± 16 hours. There were no deaths during the interventional procedures and one patient died of sepsis at the ICU 5 days after the procedure. CONCLUSION: In our experience AxA proved to be a safe and effective alternative for different interventional procedures in neonates and infants with congenital heart diseases.

INTRODUÇÃO: O forame oval patente ocorre em 27% a 30% da população e pode estar associado a eventos embólicos, dentre eles o acidente vascular cerebral criptogênico. A prótese PREMERE TM, especialmente desenvolvida para a correção do forame oval patente, apresenta baixo perfil, reduzida quantidade de metal e âncora no lado esquerdo, com reduzida superfície para minimizar o risco de formação de trombos. Avaliamos os resultados clínicos e ecocardiográficos imediatos e aos três e seis meses pósimplante do dispositivo. MÉTODO: Entre maio de 2008 e junho de 2009, a prótese foi implantada em 14 pacientes com forame oval patente e que apresentaram eventos embólicos cerebrais prévios, comprovados por tomografia computadorizada e/ou ressonância nuclear magnética de crânio. O diagnóstico ecocardiográfico de forame oval patente foi realizado quando microbolhas eram detectadas no átrio esquerdo, dentro de três ciclos cardíacos após a opacificação do átrio direito. Foram excluídos os portadores de forame oval patente com aneurisma do septo interatrial > 2 cm, e os pacientes com fibrilação/flutter atrial ou com outras afecções que explicassem o acidente vascular cerebral criptogênico. RESULTADOS: Nove (64,3%) pacientes eram do sexo masculino e a média das idades foi de 47,2 ± 17,5 anos. Observou-se sucesso do implante em 100% dos casos. O ecocardiograma transesofágico logo após o procedimento evidenciou a presença de microbolhas no átrio esquerdo, com a manobra de Valsalva, em 50% dos casos. Todos os pacientes receberam alta hospitalar no dia seguinte, em uso de ácido acetilsalicílico 200 mg/dia e clopidogrel 75 mg/dia, e retornaram com três meses para acompanhamento clínico e ecocardiográfico. O ecocardiograma transesofágico aos três meses eviden ciou discreto fluxo residual em apenas 3 (21,4%) pacientes. Esses pacientes apresentaram forame oval patente totalmente ocluído no ecocardiograma transesofágico realizado aos seis meses. Nenhum dos pacientes apresentou eventos cardiovasculares durante o período de observação. CONCLUSÃO: A prótese PREMERE TM demonstrou ser um dispositivo seguro e eficaz na oclusão do forame oval patente. A taxa de oclusão nesta experiência inicial foi elevada para um período de observação de seis meses.

BACKGROUND: Patent foramen ovale is observed in 27% to 30% of the population and may be associated to embolic events, among them the cryptogenic stroke. The PREMERE TM device, specially developed to correct patent foramen ovale, has a low profile, reduced amount of metal and a left anchor with a small total surface to minimize the risk of thrombus formation. Clinical and echocardiographic results were evaluated immediately after the procedure and 3 and 6 months after device implantation. METHOD: From May 2008 to June 2009, the device was implanted in 14 patients with patent foramen ovale with prior cerebral embolic events, confirmed by computerized tomography and/or cranial magnetic resonance imaging. Echocardiographic patent foramen ovale was diagnosed when microbubbles were detected in the left atrium within three heartbeats after opacification of the right atrium. Patients with patent foramen ovale with interatrial septal aneurysm > 2 cm, those with atrial fibrilation/flutter or with other diseases that might explain the cryptogenic stroke were excluded. RESULTS: Nine (64.3%) patients were male and mean age was 47.2 ± 17.5 years. Successful implantation was achieved in 100% of the cases. Transesophageal echocardiogram immediately after the procedure showed the presence of microbubbles in the left atrium with Valsalva maneuver in 50% of the cases. All of the patients were discharged the following day, receiving acetyl salicylic acid 200 mg/day and clopidogrel 75 mg/day and returned after 3 months for clinical and echocardiographic follow-up. The transesophageal echocardiogram at three months showed a mild residual flow in only 3 (21.4%) patients. These patients had a totally occluded patent foramen ovale at the 6-month follow-up transesophageal echocardiogram. None of the patients had cardiovascular events during the follow-up period. CONCLUSION: The PREMERE TM device proved to be safe and effective in the occlusion of patent foramen ovale. The occlusion rate in this initial experience was high for a follow-up period of 6 months.

A obstrução dos túneis intra-atriais, no pós-operatório tardio de cirurgia de correção atrial para o tratamento da transposição das grandes artérias, não é uma complicação infreqüente, podendo até, em alguns casos, ser fatal. O tratamento cirúrgico de tais lesões pode apresentar altos índices de morbidade e mortalidade. Recentemente, o tratamento percutâneo mediante implante de stent ou por meio de angioplastia com cateter-balão tem sido utilizado com bons resultados. Relatamos dois casos de tratamento percutâneo de obstruções dos túneis intra-atriais sistêmico e pulmonar.

Obstruction of the venous pathways after atrial repair for transposition of the great arteries is not uncommon and can be, in some cases, fatal. The surgical treatment of these complications is a high-risk procedure. Nowadays, percutaneous balloon angioplasty or stenting have been used with good results. We report two cases of percutaneous treatment of systemic and pulmonary "baffle" obstructions.

PURPOSE: Evaluation of the role of transesophageal echocardiography in percutaneous closure of atrial septal defects (ASD) with the Amplatzer septal occluder. METHODS: Patients were selected for percutaneous closure of ASD by transesophageal echocardiography (TEE), which was also used to monitor the procedure, helping to select the appropriate size of the Amplatzer device, to verify its position, and to access the immediate results of the procedure. During the follow-up, TEE was used to evaluate the presence and magnitude of residual shunt (RS), device position, and right cardiac chamber diameters. RESULTS: Twenty-two (40%) of a total of 55 studied patients were selected. Thirteen underwent Amplatzer device implantation, eight are still waiting for it, and one preferred the conventional surgical treatment. All procedures were successful, which was mainly due to proper patient selection. Six (23%) patients acutely developed RS, which spontaneously disapeared at the three-month follow-up examination in three patients. There was a significant reduction in the right ventricle diastolic diameter, from 27mm (average) to 24mm and 20mm, one and three months after the procedure, respectively (p<0.0076). CONCLUSION: With the aid of TEE, percutaneous closure of ASD can be successfully, safely, and effectively performed.